ANDA 210880

HETERO LABS UNIT III

FDA Drug Application

Application #210880

Documents

• Letter: 2018-08-20

Application Sponsors

ANDA 210880

HETERO LABS UNIT III

Marketing Status

• None (Tentative Approval): 001

FDA Submissions

TYPE 4; Type 4 - New Combination

ORIG

1

TA

2018-08-08

PRIORITY

Submissions Property Types

ORIG

1

Null

6

CDER Filings

HETERO LABS UNIT III

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 210880
            [companyName] => HETERO LABS UNIT III
            [docInserts] => ["",""]
            [products] => [{"drugName":"DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE","activeIngredients":"DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE","strength":"50MG;300MG;300MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"08\/08\/2018","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2018\\\/210880Orig1s000TAltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2018-08-08
        )

)